Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 7/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | ATM | Q13315 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cgs-21680 SCHEMBL12648395 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL13285993 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL14397691 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL3730487 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL2318561 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL24178317 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL724684 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL19807521 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL26629876 | 0.99 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL29381841 | 0.99 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | claimed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| EP-3280414-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | Oxford University Innovation Limited (GB) | 2018-02-14 | — | — | EP | claimed |
| WO-2017178820-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-10-19 | — | — | WO | claimed |
| WO-2016183217-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY (US) | 2016-11-17 | — | — | WO | claimed |
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2025-09-25 | — | — | US | disclosed |
| US-11931374-B2 | Adenosine receptor modulators for the treatment of circadian rhythm disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-03-19 | — | — | US | disclosed |
| EP-3280414-B1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | UNIV OXFORD INNOVATION LTD (GB) | 2023-08-23 | — | — | EP | disclosed |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | disclosed |
| US-10953015-B2 | Use of adenosine receptor signaling to regulate P-gp function | CORNELL UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| WO-2012027695-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | NORTHEASTERN UNIVERSITY (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110288478-A1 | BALLOON CATHETER EXHIBITING RAPID INFLATION AND DEFLATION | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2011-11-24 | — | — | US | disclosed |
| WO-2011143442-A1 | A METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | TROVIS PHARMACEUTICALS, LLC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110270225-A1 | METHOD FOR INCREASED UPTAKE OF BENEFICIAL AGENT AND EJECTION FRACTION BY POSTCONDITIONING PROCEDURES | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2240020-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | Pgx Health, Llc (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089425-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | PGXHEALTH LLC (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA2A 10/4885ADORA3 32/4885ADORA1 39/4885 |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
| US-11931374-B2 | Adenosine receptor modulators for the treatment of circadian rhythm disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA2A 10/4885ADORA3 32/4885ADORA1 39/4885 |
| US-20090181920-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.